Abstract
There is strong epidemiological evidence that patients with diabetes have a lower incidence of abdominal aortic aneurysm. The precise mechanism of this negative association is unknown. Whilst a number of studies have supported the hypothesis that protection is a function of diabetes-mediated changes in the vascular extracellular matrix biology, there is also support for the idea that the treatment regimens used in diabetes may afford protection against AAA. In particular the pleiotropic drug family, the thiazolidinediones have been examined as candidates to ameliorate aneurysm formation. Both the thiazolidinediones, and the structurally related family, fibrates, have been shown to have anti-inflammatory and antioxidative effects, in addition to ability to modulatate glucose and lipid homeostasis. In this brief review we present the current data exploring the use of thiazolidinediones in experimental aneurysm development. Despite the fact that both thiazolidinediones Rosiglitazone and Pioglitazone are no longer prescribed in Europe and the US, they have provided important insights into the mechanism of action, and the application of other pleiotropic drugs in the treatment of AAA. One such pleiotropic drug is high-density lipoproteins (HDLs), which have been shown to have a broad spectrum of effects, including activation of PPARs, which may favour their use as a new drug target for protection against AAA development.
Keywords: Aneurysms, diabetes, fibrates, high-density lipoproteins, peroxisome proliferator-activator receptors, thiazolidinediones.
Current Vascular Pharmacology
Title:Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Volume: 11 Issue: 3
Author(s): Evelyn Torsney, Grisha Pirianov and Gillian W. Cockerill
Affiliation:
Keywords: Aneurysms, diabetes, fibrates, high-density lipoproteins, peroxisome proliferator-activator receptors, thiazolidinediones.
Abstract: There is strong epidemiological evidence that patients with diabetes have a lower incidence of abdominal aortic aneurysm. The precise mechanism of this negative association is unknown. Whilst a number of studies have supported the hypothesis that protection is a function of diabetes-mediated changes in the vascular extracellular matrix biology, there is also support for the idea that the treatment regimens used in diabetes may afford protection against AAA. In particular the pleiotropic drug family, the thiazolidinediones have been examined as candidates to ameliorate aneurysm formation. Both the thiazolidinediones, and the structurally related family, fibrates, have been shown to have anti-inflammatory and antioxidative effects, in addition to ability to modulatate glucose and lipid homeostasis. In this brief review we present the current data exploring the use of thiazolidinediones in experimental aneurysm development. Despite the fact that both thiazolidinediones Rosiglitazone and Pioglitazone are no longer prescribed in Europe and the US, they have provided important insights into the mechanism of action, and the application of other pleiotropic drugs in the treatment of AAA. One such pleiotropic drug is high-density lipoproteins (HDLs), which have been shown to have a broad spectrum of effects, including activation of PPARs, which may favour their use as a new drug target for protection against AAA development.
Export Options
About this article
Cite this article as:
Torsney Evelyn, Pirianov Grisha and Cockerill Gillian W., Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?, Current Vascular Pharmacology 2013; 11 (3) . https://dx.doi.org/10.2174/1570161111311030003
DOI https://dx.doi.org/10.2174/1570161111311030003 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Takotsubo Cardiomyopathy
Current Pharmaceutical Design Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Circulating miR-126 as a Potential Non-invasive Biomarker for Intracranial Aneurysmal Rupture: A Pilot Study
Current Neurovascular Research The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets Matrix Metalloproteinases: A Potential Therapeutic Target in Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) Detection of the Artery of Adamkiewicz Before Open Surgery and Endovascular Aortic Repair: A Review
Current Medical Imaging Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
Current Pharmaceutical Design Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Arterial Dilatation-Related Diseases: The Prerequisite Condition of Arterial Elastic Tissue Damage and Endovascular Treatment
Recent Patents on Medical Imaging Specific TNF-alpha Inhibition in Cerebral Aneurysm formation and Subarachnoid Hemorrhage
Current Drug Safety Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Evaluation of Application Value of Transcranial Doppler (TCD) in the Inspection of Cerebral Vasospasm After the Treatment of Intracranial Aneurysm
Current Medical Imaging